Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rezatomidine SCHEMBL345466 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Rezatomidine SCHEMBL676215 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Rezatomidine SCHEMBL7799658 | 1.00 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL14546567 | 0.84 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL8510869 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL8510363 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3709658 | 0.81 | GABRA1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3749391 | 0.78 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3418059 | 0.78 | CYP1A2 (0.45) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3419587 | 0.78 | CES2 (0.33) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4565206-A1 | OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS REDUCTION AGENT | Bausch + Lomb Ireland Limited (IE) | 2025-06-11 | — | — | EP | claimed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | claimed |
| WO-2024028816-A1 | OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS REDUCTION AGENT | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-02-08 | — | — | WO | claimed |
| WO-2024028815-A1 | OPHTHALMIC COMPOSITION COMPRISING AN ANTI-ALLERGEN AND A REDNESS REDUCTION AGENT | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-02-08 | — | — | WO | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4565206-A1 | OPHTHALMIC COMPOSITION COMPRISING PILOCARPINE AND A REDNESS REDUCTION AGENT | Bausch + Lomb Ireland Limited (IE) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025111440-A1 | PHENTOLAMINE MESYLATE AND THERAPEUTIC USES THEREOF | OPUS GENETICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250162995-A1 | PHENTOLAMINE MESYLATE AND THERAPEUTIC USES THEREOF | OPUS GENETICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025102067-A1 | HYDRATION FORMULATION INCLUDING BRIMONIDINE | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-05-15 | — | — | WO | disclosed |
| EP-4552651-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | Lenz Therapeutics Operations, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240374573-A1 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC | 2024-11-14 | — | — | US | disclosed |
| EP-4228636-A1 | COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGS | Lenz Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022081204-A1 | COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGS | PRESBYOPIA THERAPIES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250162995-A1 | PHENTOLAMINE MESYLATE AND THERAPEUTIC USES THEREOF | PDE6C, PDE6D, PDE6A | ADRA2A 153/4885ADRA2B 217/4885ADRA2C 143/4885 |
| US-20240374573-A1 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ADRB2, ADRA2C, ADRA2B | ADRA2A 4/4885ADRA2B 3/4885ADRA2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.